BPTHライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:32):

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States...

Stats
本日の出来高	29 560.00
平均出来高	1.45M
時価総額	4.34M
EPS	$0 ( 2024-03-29 )
次の収益日	( $-4.54 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0800
ATR14	$0.0380 (1.37%)

Insider Trading

Date	Person	Action	Amount	type
2023-05-02	Cleaver Heath	Buy	10 000	Common Stock Option (right to buy)
2023-05-02	Aubert Paul	Buy	10 000	Common Stock Option (right to buy)
2023-05-02	Sherwood Aline	Buy	10 000	Common Stock Option (right to buy)
2023-05-02	Morris Douglas P	Buy	13 000	Common Stock Option (right to buy)
2023-05-02	Nielsen Peter Henry	Buy	105 000	Common Stock Option (right to buy)

INSIDER POWER
100.00
Last 88 transactions
Buy: 10 429 808 \| Sell: 661 335

ボリューム相関

長: -0.05 (neutral)

短: -0.10 (neutral)

Signal:(50.67) Neutral

Bio Path Holdings Inc 相関

10 最も正の相関
BDTX	0.897
PXLW	0.89
IMAB	0.88
SHYF	0.879
FULC	0.876
CPIX	0.874
RMRM	0.873
IVA	0.872
QMCO	0.871
DADA	0.87

10 最も負の相関
LEDS	-0.893
PPBT	-0.881
CINC	-0.87
ASUR	-0.86
SNCR	-0.857
SLGG	-0.851
TSLA	-0.835
MTEK	-0.834
RIBT	-0.827
XOG	-0.823

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Bio Path Holdings Inc 相関 - 通貨/商品

0.77
( moderate )

0.83
( strong )

0.00
( neutral )

0.77
( moderate )

0.49
( neutral )

-0.76
( moderate negative )

Bio Path Holdings Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-178 000 (0.00 %)
EPS:	$-33.64

FY	2023
収益:	$0
総利益:	$-178 000 (0.00 %)
EPS:	$-33.64

FY	2022
収益:	$0
総利益:	$-178 000 (0.00 %)
EPS:	$-38.03

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.550

Financial Reports:

No articles found.

Bio Path Holdings Inc

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.